{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:56:49Z","timestamp":1783133809030,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA223772"],"award-info":[{"award-number":["R01 CA223772"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170079"],"award-info":[{"award-number":["RP170079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180712"],"award-info":[{"award-number":["RP180712"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Salivary gland cancers (SGCs) are rare yet aggressive malignancies with significant histological heterogeneity, which has made prediction of prognosis and development of targeted therapies challenging. In majority of patients, local recurrence and\/or distant metastasis are common and systemic treatments have minimal impact on survival. Therefore, identification of novel targets for treatment that can also be used as predictors of recurrence for multiple histological subtypes of SGCs is an area of unmet need. In this study, we developed a novel transgenic mouse model of SGC, efficiently recapitulating the major histological subtype (adenocarcinomas of the parotid gland) of human SGC. CDK2 knock out (KO) mice crossed with MMTV-low molecular weight forms of cyclin E (LMW-E) mice generated the transgenic mouse models of SGC, which arise in the parotid region of the salivary gland, similar to the common site of origin seen in human SGCs. To identify the CDK2 independent catalytic partner(s) of LMW-E, we used LMW-E expressing cell lines in mass spectrometric analysis and subsequent biochemical validation in pull down assays. These studies revealed that in the absence of CDK2, LMW-E preferentially binds to CDK5. Molecular targeting of CDK5, using siRNA, resulted in inhibition of cell proliferation of human SGCs overexpressing LMW-E. We also provide clinical evidence of significant association of LMW-E\/CDK5 co-expression and decreased recurrence free survival in human SGC. Immunohistochemical analysis of LMW-E and CDK5 in 424 patients representing each of the four major histological subtypes of human salivary cancers (Aci, AdCC, MEC, and SDC) revealed that LMW-E and CDK5 are concordantly (positive\/positive or negative\/negative) expressed in 70% of these patients. The co-expression of LMW-E\/CDK5 (both positive) robustly predicts the likelihood of recurrence, regardless of the histological classification of these tumors. Collectively, our results suggest that CDK5 is a novel and targetable biomarker for the treatment of patients with SGC presenting with LMW-E overexpressing tumors.<\/jats:p>","DOI":"10.1038\/s41389-021-00324-z","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:02:47Z","timestamp":1620979367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers"],"prefix":"10.1038","volume":"10","author":[{"given":"Amriti R.","family":"Lulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Akli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie W.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-4702","authenticated-orcid":false,"given":"Yoshitsugu","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3511-4916","authenticated-orcid":false,"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel K.","family":"El-Naggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-0849","authenticated-orcid":false,"given":"Khandan","family":"Keyomarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"324_CR1","unstructured":"Noone A. M. et al. (eds). SEER Cancer Statistics Review. (National Cancer Institute Bethesda, MD, 1975\u20132015)."},{"key":"324_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1200\/JOP.2017.026856","volume":"14","author":"E Son","year":"2018","unstructured":"Son, E., Panwar, A., Mosher, C. H. & Lydiatt, D. Cancers of the major salivary gland. J. Oncol. Pract. 14, 99\u2013108 (2018).","journal-title":"J. Oncol. Pract."},{"key":"324_CR3","unstructured":"El-Naggar A. K., C J., Grandis J. R., Takata T., Slootweg P. J., (eds). Tumours of salivary glands. in WHO classification of head and neck tumours. 4th ed. (International Agency for Research on Cancer, Lyon, 2017). p. 159\u2013202."},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.oraloncology.2015.04.005","volume":"51","author":"A Coca-Pelaz","year":"2015","unstructured":"Coca-Pelaz, A. et al. Adenoid cystic carcinoma of the head and neck\u2014an update. Oral. Oncol. 51, 652\u2013661 (2015).","journal-title":"Oral. Oncol."},{"key":"324_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/lary.24231","volume":"124","author":"NR Patel","year":"2014","unstructured":"Patel, N. R. et al. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope 124, 172\u2013178 (2014).","journal-title":"Laryngoscope"},{"key":"324_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/1078-0432.CCR-15-2867-T","volume":"22","author":"Y Mitani","year":"2016","unstructured":"Mitani, Y. et al. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin. Cancer Res. 22, 725\u2013733 (2016).","journal-title":"Clin. Cancer Res."},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1172\/JCI67201","volume":"123","author":"PJ Stephens","year":"2013","unstructured":"Stephens, P. J. et al. Whole exome sequencing of adenoid cystic carcinoma. J. Clin. Investig. 123, 2965\u20132968 (2013).","journal-title":"J. Clin. Investig."},{"key":"324_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep13347","volume":"5","author":"Y Fu","year":"2015","unstructured":"Fu, Y. et al. Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci. Rep. 5, 13347 (2015).","journal-title":"Sci. Rep."},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.1158\/0008-5472.CAN-10-1758","volume":"70","author":"CR Diegel","year":"2010","unstructured":"Diegel, C. R., Cho, K. R., El-Naggar, A. K., Williams, B. O. & Lindvall, C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 70, 9143\u20139152 (2010).","journal-title":"Cancer Res."},{"key":"324_CR10","doi-asserted-by":"publisher","first-page":"e0128467","DOI":"10.1371\/journal.pone.0128467","volume":"10","author":"MM Szwarc","year":"2015","unstructured":"Szwarc, M. M. et al. Aberrant activation of the RANK signaling receptor induces murine salivary gland tumors. PLoS ONE 10, e0128467 (2015).","journal-title":"PLoS ONE"},{"key":"324_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/labinvest.2013.62","volume":"93","author":"AL Simons","year":"2013","unstructured":"Simons, A. L. et al. The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. Lab Investig. 93, 711\u2013719 (2013).","journal-title":"Lab Investig."},{"key":"324_CR12","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","volume":"78","author":"JA Caruso","year":"2018","unstructured":"Caruso, J. A., Duong, M. T., Carey, J. P. W., Hunt, K. K. & Keyomarsi, K. Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies. Cancer Res. 78, 5481\u20135491 (2018).","journal-title":"Cancer Res."},{"key":"324_CR13","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa021153","volume":"347","author":"K Keyomarsi","year":"2002","unstructured":"Keyomarsi, K. et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347, 1566\u20131575 (2002).","journal-title":"N. Engl. J. Med."},{"key":"324_CR14","doi-asserted-by":"publisher","unstructured":"Karakas C. et al. Cytoplasmic cyclin E expression predicts for response to neoadjuvant chemotherapy in breast cancer. Ann. Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000003551 (2019).","DOI":"10.1097\/SLA.0000000000003551"},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1158\/1078-0432.CCR-16-2217","volume":"23","author":"KK Hunt","year":"2017","unstructured":"Hunt, K. K. et al. Cytoplasmic cyclin E predicts recurrence in patients with breast cancer. Clin. Cancer Res. 23, 2991\u20133002 (2017).","journal-title":"Clin. Cancer Res."},{"key":"324_CR16","doi-asserted-by":"publisher","first-page":"15148","DOI":"10.1074\/jbc.M409789200","volume":"280","author":"H Wingate","year":"2005","unstructured":"Wingate, H. et al. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J. Biol. Chem. 280, 15148\u201315157 (2005).","journal-title":"J. Biol. Chem."},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/0008-5472.CAN-10-4086","volume":"71","author":"S Akli","year":"2011","unstructured":"Akli, S., Van Pelt, C. S., Bui, T., Meijer, L. & Keyomarsi, K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 71, 3377\u20133386 (2011).","journal-title":"Cancer Res."},{"key":"324_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","volume":"74","author":"M Guzzo","year":"2010","unstructured":"Guzzo, M. et al. Major and minor salivary gland tumors. Crit. Rev. Oncol. Hematol. 74, 134\u2013148 (2010).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"324_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/ncb1284","volume":"7","author":"E Aleem","year":"2005","unstructured":"Aleem, E., Kiyokawa, H. & Kaldis, P. Cdc2-cyclin E complexes regulate the G1\/S phase transition. Nat. Cell Biol. 7, 831\u2013836 (2005).","journal-title":"Nat. Cell Biol."},{"key":"324_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0165-6147(02)02071-0","volume":"23","author":"M Knockaert","year":"2002","unstructured":"Knockaert, M., Greengard, P. & Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharm. Sci. 23, 417\u2013425 (2002).","journal-title":"Trends Pharm. Sci."},{"key":"324_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-008-0921-5","volume":"64","author":"A Conroy","year":"2009","unstructured":"Conroy, A. et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother. Pharmacol. 64, 723\u2013732 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"324_CR22","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","volume":"113","author":"R Chen","year":"2009","unstructured":"Chen, R. et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113, 4637\u20134645 (2009).","journal-title":"Blood"},{"key":"324_CR23","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner, N. M. et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin. Cancer Res. 25, 3996\u20134013 (2019).","journal-title":"Clin. Cancer Res."},{"key":"324_CR24","doi-asserted-by":"crossref","unstructured":"Johnston S. J., et al. Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age. Cancers 12 (2012).","DOI":"10.3390\/cancers12030712"},{"key":"324_CR25","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.1158\/1078-0432.CCR-17-1544","volume":"23","author":"I Doostan","year":"2017","unstructured":"Doostan, I. et al. Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer. Clin. Cancer Res. 23, 7288\u20137300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"324_CR26","doi-asserted-by":"publisher","first-page":"14897","DOI":"10.18632\/oncotarget.14689","volume":"8","author":"A Alexander","year":"2017","unstructured":"Alexander, A. et al. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget 8, 14897\u201314911 (2017).","journal-title":"Oncotarget"},{"key":"324_CR27","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ajpath.2016.02.024","volume":"186","author":"C Karakas","year":"2016","unstructured":"Karakas, C. et al. Cytoplasmic cyclin E and phospho-cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer. Am. J. Pathol. 186, 1900\u20131912 (2016).","journal-title":"Am. J. Pathol."},{"key":"324_CR28","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1128\/MCB.21.18.6254-6269.2001","volume":"21","author":"DC Porter","year":"2001","unstructured":"Porter, D. C. et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol. Cell Biol. 21, 6254\u20136269 (2001).","journal-title":"Mol. Cell Biol."},{"key":"324_CR29","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1158\/0008-5472.CAN-07-0599","volume":"67","author":"S Akli","year":"2007","unstructured":"Akli, S. et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 67, 7212\u20137222 (2007).","journal-title":"Cancer Res."},{"key":"324_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ydbio.2009.01.019","volume":"328","author":"R Fernandez-Valdivia","year":"2009","unstructured":"Fernandez-Valdivia, R. et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 328, 127\u2013139 (2009).","journal-title":"Dev. Biol."},{"key":"324_CR31","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/0092-8674(91)90044-Y","volume":"66","author":"A Koff","year":"1991","unstructured":"Koff, A. et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66, 1217\u20131228 (1991).","journal-title":"Cell"},{"key":"324_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/35096019","volume":"2","author":"R Dhavan","year":"2001","unstructured":"Dhavan, R. & Tsai, L. H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749\u2013759 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"324_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.tcb.2011.11.003","volume":"22","author":"ZH Cheung","year":"2012","unstructured":"Cheung, Z. H. & Ip, N. Y. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 22, 169\u2013175 (2012).","journal-title":"Trends Cell Biol."},{"key":"324_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/his.12183","volume":"63","author":"T Nakano","year":"2013","unstructured":"Nakano, T. et al. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status. Histopathology 63, 378\u2013392 (2013).","journal-title":"Histopathology"},{"key":"324_CR35","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/modpathol.2011.86","volume":"24","author":"LB Brill 2nd","year":"2011","unstructured":"Brill, L. B. 2nd et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod. Pathol. 24, 1169\u20131176 (2011).","journal-title":"Mod. Pathol."},{"key":"324_CR36","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-11-1870","volume":"17","author":"Y Mitani","year":"2011","unstructured":"Mitani, Y. et al. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin. Cancer Res. 17, 7003\u20137014 (2011).","journal-title":"Clin. Cancer Res."},{"key":"324_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ng.2643","volume":"45","author":"AS Ho","year":"2013","unstructured":"Ho, A. S. et al. The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 45, 791\u2013798 (2013).","journal-title":"Nat. Genet."},{"key":"324_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00324-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:35:24Z","timestamp":1669822524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00324-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1038\/s41389-021-00324-z","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K.H. is on the medical advisory board for Armada Health and Merck & Co. and receives research funding from Endomagnetics, Lumicell.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"40"}}